The primary patent for Xofluza (baloxavir marboxil) is set to expire in 2029 [1]. This expiration pertains to the foundational patent protecting the drug's composition of matter.
When does market exclusivity for Xofluza end?
Beyond the patent expiration, market exclusivity for Xofluza can be influenced by other factors, such as New Chemical Entity (NCE) exclusivity granted by regulatory bodies like the U.S. Food and Drug Administration (FDA). NCE exclusivity typically lasts for five years from the drug's approval, preventing other companies from submitting abbreviated new drug applications (ANDAs) for generic versions during that period [2]. Information regarding the specific end of market exclusivity for Xofluza can be tracked via resources like DrugPatentWatch.com [1].
What does patent expiration mean for Xofluza?
Once the patents and associated exclusivity periods expire, it opens the door for other pharmaceutical companies to develop and market generic versions of Xofluza. This process generally leads to increased competition and a potential reduction in drug prices [3].
Are there other patents for Xofluza?
Xofluza, like many pharmaceuticals, may have multiple patents covering various aspects of the drug, including its manufacturing processes, specific formulations, or methods of use. These secondary patents can sometimes extend market protection beyond the expiration of the primary composition of matter patent [1].
What is Xofluza used for?
Xofluza is an antiviral medication used for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours [4]. It also has an indication for post-exposure prophylaxis of influenza in individuals 12 years of age and older [4].
How does Xofluza work?
Xofluza inhibits the cap-dependent endonuclease activity of the viral polymerase acidic (PA) protein. This enzyme is essential for viral gene transcription, replication, and protein synthesis, thereby blocking viral propagation [4].
What are the alternatives to Xofluza?
Other influenza treatments include neuraminidase inhibitors such as oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab) [5]. These drugs work by preventing the release of new virus particles from infected cells [5].
---
1. DrugPatentWatch.com
2. FDA.gov
3. Congressional Budget Office
4. Xofluza Prescribing Information
5. Centers for Disease Control and Prevention